• Histologically confirmed invasive breast or ovarian cancer (Stage I, II, III, or IV) as per AJCC 8th Edition, 2018 Staging Criteria.

• Must be planning to receive paclitaxel weekly for 12 weeks (12 weeks total) as part of neoadjuvant, adjuvant, or metastatic cancer treatment.

‣ Concurrent biologic therapy (e.g., trastuzumab and pertuzumab) is allowed.

⁃ Currently receiving hormone therapy, bisphosphonates, denosumab or LHRH-agonists is allowed.

⁃ Concurrent use of immune checkpoint inhibitor therapy is allowed.

⁃ (Neo)adjuvant chemotherapy with doxorubicin and cyclophosphamide is allowed.

⁃ Concurrent use of carboplatin with weekly paclitaxel in the study is allowed.

• May participate concurrently in other cancer trials.

• Must be able to complete questionnaires in English or Spanish.

• Age ≥ 18 years old at the time of consent.

• ECOG performance status of 0 - 1 (Karnofsky scale ≥ 70%, see Appendix).

• Ability to understand and the willingness to sign a written informed consent document.

• Individuals of child-bearing potential must agree to use birth control (e.g., hormonal or barrier method; abstinence, an intrauterine device) prior - to study entry, for the duration of study participation (including dose interruptions), and for 3 months after the last dose of tart cherry juice supplement; or be surgically sterilized (e.g., hysterectomy or tubal ligation).

• Patients with known human immunodeficiency virus (HIV) are allowed in the study, but HIV-positive patients must have:

‣ A stable regimen of highly active anti-retroviral therapy (HAART)

⁃ No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

⁃ A CD4 count above 250 cells/µL and an undetectable HIV viral load on standard PCR-based tests within the last year.

• Stated willingness to not drink any additional tart cherry or any cherry juice while on the study.

• Ability and willingness to adhere to the study visit schedule and other protocol requirements